Search our site 
 
Advanced Search
 
Home | Exam dates | Contact us | About us | Testimonials |
 
 

map
You are in Home >> Intensive Care >> Sepsis >> Metabolic & Cytokine Therapies >> Potential therapies: Literature


Vincent et al. The ENHANCE trial. CCM 2005

Created: 21/5/2007
Updated: 21/5/2007
 

Reference

Vincent JL, Bernard GR, Beale R et al.
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
Crit Care Med 2005; 33(10): 2266-77

Major finding

ENHANCE provides supportive evidence for the favorable benefit/risk ratio observed in the PROWESS trial and suggests that more effective use of activated protein C might be obtained by initiating therapy earlier.


ArticleDate:20070521
SiteSection: Article
 
   
    
                                            
  Posting rules

     To view or add comments you must be a registered user and login  




Login Status  

You are not currently logged in.
UK/Ireland Registration
Overseas Registration

  Forgot your password?








 
All rights reserved © 2021. Designed by AnaesthesiaUK.

{Site map} {Site disclaimer} {Privacy Policy} {Terms and conditions}

 Like us on Facebook 

vp